Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party

Measurable residual disease (MRD; previously termed minimal residual disease) is an independent, postdiagnosis, prognostic indicator in acute myeloid leukemia (AML) that is important for risk stratification and treatment planning, in conjunction with other well-established clinical, cytogenetic, and...

Full description

Bibliographic Details
Main Authors:	Schuurhuis, G, Heuser, M, Freeman, S, Béné, M, Buccisano, F, Cloos, J, Grimwade, D, Haferlach, T, Hills, R, Hourigan, C, Jorgensen, J, Kern, W, Lacombe, F, Maurillo, L, Preudhomme, C, Van Der Reijden, B, Thiede, C, Venditti, A, Vyas, P, Wood, B, Walter, R, Döhner, K, Roboz, G, Ossenkoppele, G
Format:	Journal article
Language:	English
Published:	American Society of Hematology 2018

Similar Items

Molecular MRD status and outcome after transplantation in NPM1-mutated AML
by: Dillon, R, et al.
Published: (2020)

Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.
by: van de Loosdrecht, A, et al.
Published: (2009)

BCL-2 inhibitor and conventional chemotherapy combinations for acute myeloid leukemia: shifting from the unfit to the fit patient with AML
by: Ossenkoppele, G, et al.
Published: (2020)

The importance of diagnostic cytogenetics in older patients with AML: Analysis of 922 patients entered into the MRC AML 11 trial.
by: Grimwade, D, et al.
Published: (1999)

Impact of diagnostic cytogenetics on outcome in AML: Analysis of 1,613 patients entered into the UK MRC AML 10 trial.
by: Grimwade, D, et al.
Published: (1996)

A reexamination of MRD-based word sense disambiguation
by: Baldwin, Timothy, et al.
Published: (2011)

Detection of minimal residual disease (MRD) in APL by "real-time" RT-PCR: Analysis of cases entered into the UK MRC ATRA trial.
by: Grimwade, D, et al.
Published: (1999)

The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial.
by: Grimwade, D, et al.
Published: (2001)

MRD-based word sense disambiguation : further extending lesk
by: Baldwin, Timothy, et al.
Published: (2010)

Genotype-specific MRD interpretation improves stratification in paediatric acute lymphoblastic leukaemia
by: O'Connor, D, et al.
Published: (2017)

The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties.
by: Grimwade, D, et al.
Published: (1998)

Comparison of clinical significance of MRD as determined by IgH genescanning or allele specific probing in childhood ALL.
by: Moppett, J, et al.
Published: (2002)

MULTICENTRE VALIDATION OF A REPRODUCIBLE FLOW CYTOMETRIC SCORE FOR THE DIAGNOSIS OF LOWRISK MYELODYSPLASTIC SYNDROMES: RESULTS OF A EUROPEAN LeukemiaNET STUDY
by: Picone, C, et al.
Published: (2011)

Multicenter validation of a reproducible flow cytometric score for the diagnosis of low-grade myelodysplastic syndromes: results of a European LeukemiaNET study.
by: Della Porta, MG, et al.
Published: (2012)

Applicability and reproducibility of acute myeloid leukaemia stem cell assessment in a multi‐centre setting
by: Hanekamp, D, et al.
Published: (2020)

The graft-versus-leukemia effect in AML
by: Sweeney, C, et al.
Published: (2019)

Cytogenetic-specific heterogeneity in the kinetics of minimal residual disease (MRD) clearance in childhood acute lymphoblastic leukaemia (ALL)
by: Moorman, A, et al.
Published: (2007)

Mechanisms of response and resistance to AML therapies
by: Stoilova, B, et al.
Published: (2020)

Modernizing the preparation of the Malaysian mixed rice dish (MRD) with cook-chill central kitchen and implementation of HACCP
by: Noor Hasnan, Noor Zafira, et al.
Published: (2020)

AML associated with previous cytotoxic therapy, MDS or myeloproliferative disorders: results from the MRC's 9th AML trial.
by: Hoyle, C, et al.
Published: (1989)

Del(9q) AML: Clinical, cytological and cytogenetic characteristics and prognostic implications for patients entering the MRC AML trials.
by: Peniket, A, et al.
Published: (1999)

CYTOLOGICAL FEATURES WITH PROGNOSTIC-SIGNIFICANCE IN AML
by: Swirsky, D, et al.
Published: (1983)

AML-399 A phase 2, open-label, multiarm, multicenter study to evaluate magrolimab combined with antileukemia therapies for first-line, relapsed/refractory, or maintenance treatment of acute myeloid leukemia (AML)
by: Vyas, P, et al.
Published: (2022)

Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial
by: Freeman, SD, et al.
Published: (2023)

Monoclonal antibodies differentiating between monocytic and nonmonocytic variants of AML.
by: Linch, D, et al.
Published: (1984)

Genomic characterization of AML with aberrations of chromosome 7: a multinational cohort of 519 patients
by: Halik, A, et al.
Published: (2024)

High bax expression modulates response to treatment and survival in AML.
by: Truran, L, et al.
Published: (1999)

Attenuated arsenic trioxide plus ATRA therapy for newly diagnosed and relapsed APL: Long-term follow-up of the AML17 trial
by: Russell, N, et al.
Published: (2018)

Amplification of AML1 in acute lymphoblastic leukemia is associated with a poor outcome.
by: Robinson, H, et al.
Published: (2003)

Del (9q) AML: clinical and cytological characteristics and prognostic implications.
by: Peniket, A, et al.
Published: (2005)

ETV6/AML1 fusion by FISH in adult acute lymphoblastic leukemia
by: Al-Obaidi, M, et al.
Published: (2002)

Core Circadian Clock Genes Regulate Leukemia Stem Cells in AML
by: Puram, Rishi V., et al.
Published: (2018)

Telomere length is an independent prognostic marker in MDS but not in de novo AML
by: Williams, J, et al.
Published: (2017)

Gene expression profiling in MDS and AML: potential and future avenues.
by: Theilgaard-Mönch, K, et al.
Published: (2011)

AML-464 Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in frontline patients with TP53-mutated acute myeloid leukemia (AML): Phase 1b results
by: Daver, N, et al.
Published: (2022)

Differential Analysis of Genetic, Epigenetic, and Cytogenetic Abnormalities in AML
by: Islam, M., et al.
Published: (2017)

Transient Abnormal Myelopoiesis and AML in Down Syndrome: an Update.
by: Bhatnagar, N, et al.
Published: (2016)

Molecular characterization of the chromosome 9q deletion in AML.
by: Side, L, et al.
Published: (2000)

Molecular monitoring of residual disease (MRD) during induction and intensification phases in low risk adult B cell ALL treated according to the MRC UKALL12 protocol.
by: Foroni, L, et al.
Published: (2005)

Outcomes of relapsed/refractory patients with IDH1/2 mutated AML treated with non-targeted therapy: results from the NCRI AML trials
by: Hills, R, et al.
Published: (2018)